Stenosing Crohn’s disease of the upper gastrointestinal tract: a diagnostic challenge

Crohn’s disease (CD) with isolated lesions of the upper gastrointestinal tract occurs in less than 5% of patients. In most cases, the complication of this form of the disease is gastroduodenal obstruction, which requires surgical intervention. Aim: to describe a clinical case of CD with an atypical onset mimicking Helicobacter pylori-associated gastric ulcer.

Materials and methods. A clinical case of CD simulating gastric ulcer in a 12-year girl is presented. A comprehensive laboratory and instrumental examination of the patient was performed. The diagnosis was made: CD A1b of the upper gastrointestinal tract, ileitis, colitis (L3+L4a), stricturating form (B2) with perianal changes (p), without growth retardation (G0).

Results. Taking into account the severe course and stenosing form of CD, severe protein and energy deficiency, to prevent complications, the patient initiated biological therapy with infliximab at the rate of 5 mg/kg, administration in the standard regimen in combination with azathioprine 50 mg/day (1.5 mg/kg/day). Against the background of the treatment and dietary correction, there was a positive trend in the form of relief of vomiting and weight gain (during the hospital stay, the patient gained 4 kg in weight).

Conclusion. The use of a multidisciplinary approach made it possible to establish the diagnosis of the stenosing form of CD with a predominant involvement of the upper digestive tract. Biological therapy using infliximab in combination with both azathioprine and diet therapy made it possible to avoid surgical intervention.

Contribution:
Gorelova E.S., Potapov A.S., Alkhasov A.B. — concept and design of the study;
Gorelova E.S., Parakhina D.V., Korolev G.A., Ratnikov S.A., Sokolov I. — collection and processing of the material;
Gorelova E.S., Parakhina D.V. — writing the text;
Potapov A.S., Lokhmatov M.M., Borovik T.E. — editing the text.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: April 07, 2025
Accepted: May 20, 2025
Published: June 27, 2025

1. Ruemmele F.M., Veres G., Kolho K.L., Griffiths A., Levine A., Escher J.C., et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J. Crohns Colitis. 2014; 8(10): 1179–207. https://doi.org/10.1016/j.crohns.2014.04.005

2. van Rheenen P.F., Aloi M., Assa A., Bronsky J., Escher J.C., Fagerberg U.L., et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN Guideline Update. J. Crohns Colitis. 2020; jjaa161. https://doi.org/10.1093/ecco-jcc/jjaa161

3. Yamamoto-Furusho J.K., Parra-Holguín N.N. Diagnostic delay of inflammatory bowel disease is significantly higher in public versus private health care system in Mexican patients. Inflamm. Intest. Dis. 2022; 7(2): 72–80. https://doi.org/10.1159/000520522

4. Fedulova E.N., Shirokova N.Yu., Petrova K.S. Crohn’s disease under the guise of appendicitis. Eksperimentalnaya i klinicheskaya gastroenterologiya. 2022; (1): 140–4. https://doi.org/10.31146/1682-8658-ecg-197-1-140-144 https://elibrary.ru/qjzcsv (in Russian)

5. Dolinger M., Torres J., Vermeire S. Crohn’s disease. Lancet. 2024; 403(10432): 1177–91. https://doi.org/10.1016/s0140-6736(23)02586-2

6. Uspenskiy Yu.P., Gulunov Z.Kh., Korbesova N.G. Crohn’s disease: lesion of the esophagus, stomach and duodenum. University Therapeutic Journal. 2024; 6(2): 32–45. https://doi.org/10.56871/UTJ.2024.32.24.004 https://elibrary.ru/motkfn (in Russian)

7. Kim E.S., Park J.H., Choe Y.H., Kim M.J. Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature. Intest. Res. 2021; 19(4): 472–7. https://doi.org/10.5217/ir.2020.00072

8. Budkina T.N., Lokhmatov M.M., Tupylenko A.V., Oldakovsky V.I., Korolev G.A., Yablokova E.A., et al. Clinical guidelines for endoscopic diagnosis and monitoring of Crohn’s disease in children (draft). Eksperimentalnaya i klinicheskaya gastroenterologiya. 2023; 209(1): 87–97. https://doi.org/10.31146/1682-8658-ecg-209-1-87-97 https://elibrary.ru/klgdtx (in Russian)

9. Kim E.S., Kim M.J. Upper gastrointestinal tract involvement of Crohn disease: clinical implications in children and adolescents. Clin. Exp. Pediatr. 2022; 65(1): 21–8. https://doi.org/10.3345/cep.2021.00661

10. Turner D., Ricciuto A., Lewis A., D’Amico F., Dhaliwal J., Griffiths A.M., et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021; 160(5): 1570–83. https://doi.org/10.1053/j.gastro.2020.12.031

11. Colombel J.F., D’haens G., Lee W.J., Petersson J., Panaccione R. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J. Crohns Colitis. 2020; 14(2): 254–66. https://doi.org/10.1093/ecco-jcc/jjz131

12. Lv Y., Lou Y., Yang G., Luo Y., Lou J., Cheng Q., et al. Outcomes of pediatric patients with Crohn’s disease received infliximab or exclusive enteral nutrition during induction remission. Gastroenterol. Res. Pract. 2022; 2022: 3813915. https://doi.org/10.1155/2022/3813915